Amylyx to Spotlight Breakthrough Hypoglycemia Drug Avexitide at ENDO 2025 Investor Event

Author: Benzinga Newsdesk | July 08, 2025 06:03am

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that it will host an investor event at the Endocrine Society's annual meeting (ENDO 2025) on Sunday, July 13, 2025, at 6:00 p.m. PT, both in-person in San Francisco, California and virtually. Speakers will discuss the current burden of post-bariatric hypoglycemia (PBH) and background on avexitide, a potential first-in-class GLP-1 receptor antagonist with FDA breakthrough therapy designation. Speakers will also review new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide in post-bariatric hypoglycemia, which will be presented during ENDO 2025. These data include composite rates of Level 2 and 3 hypoglycemic events in both trials as well as new pharmacokinetic (PK) and pharmacodynamic (PD) data demonstrating continuous pharmacologic activity of the 90 mg once daily dose regimen for a 24-hour period.

Amylyx' management team will be joined by the following experts at the event:

• Marilyn Tan, MD, FACE, Principal Investigator of the LUCIDITY clinical trial, Co-Lead Investigator of the Phase 2 PREVENT Clinical Trial, and Clinical Associate Professor of Medicine at Stanford University School of Medicine
• Helen Lawler, MD, Investigator on the LUCIDITY Clinical Trial, Co-Lead Investigator of the Phase 2 PREVENT Clinical Trial, and Associate Professor of Medicine in Endocrinology at University of Colorado at Denver School of Medicine
• Colleen Craig, MD, Co-lead Investigator of Proof-of-Concept and First-in-Human Studies of Avexitide in PBH, led the avexitide development program during the Phase 2 PREVENT Clinical Trial, and Scientific Advisor and Consultant for Amylyx

Posted In: AMLX